IASLC

IASLC stands for the International Association for the Study of Lung Cancer, a global nonprofit organization of physicians, scientists, and researchers dedicated to thoracic cancers including lung cancer and mesothelioma. The IASLC develops the staging systems and pathology standards used worldwide to classify these diseases, including the TNM staging system for mesothelioma. Its consensus statements and guidelines are widely cited in both medical practice and asbestos litigation.

Origin

The IASLC was founded in 1974 in Florence, Italy, as the first multidisciplinary international organization focused on lung cancer. Over time its scope expanded to include malignant pleural mesothelioma and other thoracic malignancies, and it now partners with the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) to publish the official TNM staging manuals.

Significance in Asbestos Context

For patients with mesothelioma or asbestos-related lung cancer, the IASLC matters because its staging system is almost certainly what your oncologist used to describe how advanced your disease is, and its pathology guidelines shape how your biopsy was interpreted. In litigation, expert witnesses on both sides frequently rely on IASLC publications to define the disease, justify prognosis estimates, and support damages calculations tied to life expectancy. The IASLC's Mesothelioma Staging Project, which pooled patient data from centers worldwide, produced the 8th and 9th edition TNM staging criteria that courts and physicians now treat as the global standard.

Example Sentence

The oncologist explained that her pleural mesothelioma was classified as Stage II under the IASLC's most recent staging system, which would be important context for both her treatment plan and her legal claim.

Related Terms

TNM Staging, Malignant Pleural Mesothelioma, Histological Subtype, Pathology Report, AJCC, Prognosis

Notes

• Ask your oncologist which edition of the IASLC/AJCC staging system was used for your diagnosis (currently the 8th edition, with the 9th edition rolling out). The edition can affect prognosis discussions and expert testimony.
• Request a copy of your full pathology report and staging documentation; these records are central evidence in any asbestos claim and should be preserved.
• If you are considering surgery or a clinical trial, ask whether your treating center participates in IASLC databases or follows IASLC consensus guidelines for mesothelioma management.
• For legal purposes, your attorney's medical experts will likely cite IASLC publications when establishing diagnosis, stage, and life expectancy. Make sure your medical records clearly document the staging used.